☆ 4.7 Article

2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Volume 81, Issue 18, Pages 1835-1878

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jacc.2023.03.393

Keywords

ACC Expert Consensus Decision Pathway; cardiomyopathy; dyspnea; edema; guideline-directed medical therapy; heart failure with preserved ejection fraction

Categories

Cardiac & Cardiovascular Systems

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models

Jason Roh, Joseph A. Hill, Abhilasha Singh, Maria Valero-Munoz, Flora Sam

Summary: Heart failure with preserved ejection fraction (HFpEF) is a major challenge in cardiovascular medicine. Limited success has been achieved in developing therapies due to the incomplete understanding of its pathophysiology and the heterogeneity of clinical phenotypes. This review proposes a preclinical research strategy that focuses on model diversification to better align with our evolving understanding of HFpEF heterogeneity. The importance of developing clinically relevant models and the insights provided by currently available models are discussed.

CIRCULATION RESEARCH (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Failure With Preserved Ejection Fraction

Barry A. Borlaug, Kavita Sharma, Sanjiv J. Shah, Jennifer E. Ho

Summary: The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing due to aging, obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in understanding its pathophysiological effects and introduction of new diagnosis approaches, HFpEF remains under-recognized. This is concerning as effective treatments have been identified. This article provides an in-depth examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF. (J Am Coll Cardiol 2023;81:1810-1834) (c) 2023 by the American College of Cardiology Foundation.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Letter Medicine, General & Internal

Dapagliflozin in Heart Failure with Preserved Ejection Fraction

Elric Zweck, Ralf Westenfeld, Bjorn Redfors, Elmir Omerovic, Robin A. P. Weir, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Zuccala, Scott D. Solomon, Muthiah Vaduganathan, John J. V. McMurray

Summary: Solomon et al. report on the DELIVER trial, which showed that dapagliflozin reduced risks of heart failure-related outcomes in patients with a mildly reduced or preserved left ventricular ejection fraction. These findings are expected to influence guidelines and clinical practice. The trial also confirmed dapagliflozin's efficacy in patients with a left ventricular ejection fraction of 60% or above.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Joao P. Ferreira, Edimar Bocchi, Michael Boehm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela, Nadia Giannetti, Juan Esteban Gomez-Mesa, Stefan Janssens, James L. Januzzi, Jose R. Gonzalez-Juanatey, Bela Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Pina, Piotr Ponikowski, Michele Senni, David Sim, Jindrich Spinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragos Vinereanu, Jian Zhang, Peter Carson, Carolyn Su Ping Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet M. Schnee, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, Milton Packer

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction

Jay Patel, Negin Rassekh, Gregg C. Fonarow, Prakash Deedwania, Farooq H. Sheikh, Ali Ahmed, Phillip H. Lam

Summary: Guideline-directed medical therapy (GDMT) is the cornerstone of pharmacological treatment for patients with heart failure with reduced ejection fraction (HFrEF) and includes four main drug classes: renin-angiotensin system inhibitors, evidence-based beta-blockers, mineralocorticoid inhibitors, and sodium glucose cotransporter 2 inhibitors. The recommendation for GDMT use is based on multiple large randomized controlled trials that have shown improved clinical outcomes in HFrEF patients. However, there is underutilization of GDMT due to a lack of knowledge on how to initiate and titrate these medications safely and effectively. This review article aims to describe the different drug classes in GDMT and provide guidance on initiation and titration in both inpatient and outpatient settings.

DRUGS (2023)

Add to Collection

Letter Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Debdatta Bhattacharyya, Ayan Kar, Saurabh Dhumale, Filippos K. Triposkiadis, Andrew Xanthopoulos, Efstathios K. Iliodromitis, James Amato, Hiddo J. L. Heerspink, Lesley Inker, Tom Greene, Stefan D. Anker, Javed Butler, Milton Packer

Summary: In patients with heart failure and preserved ejection fraction, Empagliflozin reduced the incidence of primary outcome events compared to other drugs, but had higher rates of cardiovascular death, death from any cause, and hospitalization for heart failure compared to spironolactone.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Heart Failure With Preserved Ejection Fraction: A Review

Margaret M. Redfield, Barry A. Borlaug

Summary: HFpEF affects approximately 3 million people in the US and up to 32 million people worldwide, and risk factors include older age, hypertension, diabetes, dyslipidemia, and obesity. First-line therapy for HFpEF includes sodium-glucose cotransporter type 2 inhibitors, exercise, HF self-care, loop diuretics as needed, and weight loss for patients with obesity and HFpEF.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction

Sebastian Rosch, Karl-Patrik Kresoja, Christian Besler, Karl Fengler, Anne Rebecca Schoeber, Maximilian von Roeder, Christian Luecke, Matthias Gutberlet, Karin Klingel, Holger Thiele, Karl-Philipp Rommel, Philipp Lurz

Summary: In this study, patients with heart failure with preserved ejection fraction (HFpEF) were stratified based on left ventricular ejection fraction (LVEF), resulting in distinct morphologic and pathophysiologic subphenotypes. Patients with LVEF ranging from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction, while patients with LVEF >60% exhibited a hypercontractile state with excessive left ventricular afterload and diminished preload reserve.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging

Otto A. Smiseth, Daniel A. Morris, Nuno Cardim, Maja Cikes, Victoria Delgado, Erwan Donal, Frank A. Flachskampf, Maurizio Galderisi, Bernhard L. Gerber, Alessia Gimelli, Allan L. Klein, Juhani Knuuti, Patrizio Lancellotti, Julia Mascherbauer, Davor Milicic, Petar Seferovic, Scott Solomon, Thor Edvardsen, Bogdan A. Popescu

Summary: Heart failure with preserved ejection fraction (HFpEF) has a prognosis similar to heart failure with reduced EF (HFrEF), but treatment options are limited. HFpEF may involve a wide range of pathological processes, which can be differentiated using multimodality imaging.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

NAD+ Repletion Reverses Heart Failure With Preserved Ejection Fraction

Dan Tong, Gabriele G. Schiattarella, Nan Jiang, Francisco Altamirano, Pamela A. Szweda, Abdallah Elnwasany, Dong I. Lee, Heesoo Yoo, David A. Kass, Luke I. Szweda, Sergio Lavandero, Eric Verdin, Thomas G. Gillette, Joseph A. Hill

Summary: The study demonstrated through a mouse model that HFpEF is associated with myocardial mitochondrial dysfunction, and NAD(+) supplementation is considered a promising therapeutic approach.

CIRCULATION RESEARCH (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Metabolic inflammation in heart failure with preserved ejection fraction

Gabriele G. Schiattarella, Daniele Rodolico, Joseph A. Hill

Summary: HFpEF is a common chronic cardiovascular disease, where metabolic disturbance and inflammatory burden play important roles in its pathogenesis. The interplay between these two processes is complex, with metabolic inflammation having a central role in shaping the pathophysiology of HFpEF.

CARDIOVASCULAR RESEARCH (2021)

Add to Collection

Review Medicine, Research & Experimental

The immunology of heart failure with preserved ejection fraction

Charles Duncan Smart, Meena S. Madhur

Summary: HFpEF is a highly morbid, heterogeneous syndrome lacking effective therapies. Inflammation has been identified as a potential contributor to its pathogenesis, with risk factors such as obesity, hypertension, aging, and renal dysfunction being associated with chronic inflammation. However, the exact mechanisms by which inflammation contributes to HFpEF remain poorly understood.

CLINICAL SCIENCE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy of guideline-directed medical treatment in heart failure with mildly reduced ejection fraction

Xinxin Zhang, Yuxi Sun, Yunlong Zhang, Ning Wang, Qiuyan Sha, Songqi Yu, Xin Lv, Zijie Ding, Yanli Zhang, Gary Tse, Ying Liu

Summary: This study suggests that the combined use of neurohormonal antagonists in patients with HFmrEF can significantly reduce the occurrence of rehospitalization and death.

ESC HEART FAILURE (2023)

Add to Collection

Article Medicine, General & Internal

Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges

Mi-Hyang Jung, Mi-Seung Shin

Summary: The prevalence of heart failure with preserved ejection fraction (HFpEF) has increased in recent decades, particularly obesity-related HFpEF. However, the diagnosis of obesity-related HFpEF is complex. Despite the introduction of promising drugs, the management of obesity-related HFpEF has not been established. This review summarizes the diagnostic challenges, pathophysiology, and therapeutic options for obesity-related HFpEF.

KOREAN JOURNAL OF INTERNAL MEDICINE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction

Virginia S. Hahn, Christopher Petucci, Min-Soo Kim, Kenneth C. Bedi, Hanghang Wang, Sumita Mishra, Navid Koleini, Edwin J. Yoo, Kenneth B. Margulies, Zoltan Arany, Daniel P. Kelly, David A. Kass, Kavita Sharma

Summary: In patients with heart failure with preserved ejection fraction (HFpEF), despite high prevalence of obesity and diabetes, myocardial fatty acid metabolism is lower and branched-chain amino acid (BCAA) metabolism is higher compared with heart failure with reduced ejection fraction (HFrEF), suggesting inadequate fuel utilization in HFpEF.

CIRCULATION (2023)

Add to Collection

Article Peripheral Vascular Disease

Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events

Leo F. Buckley, William L. Baker, Benjamin W. Van Tassell, Jordana B. Cohen, Omar Alkhezi, Adam P. Bress, Dave L. Dixon

Summary: The study found that the amount of time spent within the target range for blood pressure is associated with adverse kidney and cardiovascular events. Better blood pressure control in hypertensive patients is linked to a lower risk of kidney and cardiovascular problems.

HYPERTENSION (2023)

Add to Collection

Review Pharmacology & Pharmacy

A stepwise approach to prescribing novel lipid-lowering medications

Hessam Kakavand, Maryam Aghakouchakzadeh, Ali Shahi, Salim S. Virani, Dave L. Dixon, Benjamin W. Van Tassell, Azita H. Talasaz

Summary: Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease, and traditional statin therapy may not be sufficient for all patients. Several new lipid lowering medications have been approved in recent years, but their global utilization remains limited. To assist clinicians in developing more effective lipid lowering treatment plans, this review proposes a practical stepwise approach that includes information on the efficacy, precautions, and monitoring parameters for each medication class.

JOURNAL OF CLINICAL LIPIDOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association

Bruce A. Warden, John R. Guyton, Adrienne C. Kovacs, Jessica A. Durham, Laney K. Jones, Dave L. Dixon, Terry A. Jacobson, P. Barton Duell

Summary: Statin-associated muscle symptoms (SAMS) are common and can lead to increased cardiovascular risk. The prevalence of SAMS ranges from 10% for all muscle symptoms related to statin use to 1-2% for pharmacological SAMS. SAMS may result from a combination of pharmacological and nonpharmacological effects, and addressing them is important for patient care.

JOURNAL OF CLINICAL LIPIDOLOGY (2023)

Add to Collection

Review Rehabilitation

A scoping review of cervical spine evaluation in standardised clinical concussion evaluation tools

Alexandru Mohai, Jack Gifford, Rebecca Herkt, Alexia Parker, Aiden Toder, Dave Dixon, Ewan Kennedy

Summary: This study aimed to identify various standardized clinical concussion evaluation tools and examine if they include cervical spine evaluation. Results showed that few tools cover cervical spine evaluation, especially physical examination. Recommendations include screening for dangerous mechanisms of injury, neurological deficit, distracting injury, and neck pain, as well as physical examination of neck range of motion and neck tenderness for post-concussion cervical spine evaluation.

PHYSICAL THERAPY IN SPORT (2022)

Add to Collection

Review Peripheral Vascular Disease

ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights

Stacey Cutrell, Ibrahim S. S. Alhomoud, Anurag Mehta, Azita H. H. Talasaz, Benjamin Van Tassell, Dave L. L. Dixon

Summary: This review discusses the discovery and development of ACE inhibitors as antihypertensive agents, compares their efficacy, tolerability, and safety to ARBs, and highlights the contemporary issues surrounding ACE inhibitor use for HTN.

CURRENT HYPERTENSION REPORTS (2023)

Add to Collection

Article Endocrinology & Metabolism

Effects of Intensive Systolic Blood Pressure Lowering on End-Stage Kidney Disease and Kidney Function Decline in Adults With Type 2 Diabetes Mellitus and Cardiovascular Risk Factors: A Post Hoc Analysis of ACCORD-BP and SPRINT

Yahya M. K. Tawfik, Benjamin W. Van Tassell, Dave L. Dixon, William L. Baker, John Fanikos, Leo F. Buckley

Summary: This study aimed to investigate the effects of intensive systolic blood pressure (SBP) lowering on the risk of major adverse kidney outcomes in individuals with type 2 diabetes mellitus and/or prediabetes and cardiovascular risk factors. The results suggest that intensive SBP lowering does not increase the risk of major adverse kidney events in individuals with type 2 diabetes and cardiovascular risk factors.

DIABETES CARE (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome

Francesco Moroni, Michael P. Ayers, Dave L. Dixon, Antonio Abbate

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Comparison of Safety and Biological Efficacy of Anakinra (Kineret) Dispensed in Polycarbonate Plastic versus Borosilicate Glass Syringes: A Patient-Level Analysis of VCUART2 and VCUART3 Clinical Trials

Azita H. Talasaz, Robin Sculthorpe, Mary Pak, Michael Lipinski, Charlotte Roberts, Roshanak Markley, Cory R. Trankle, Justin M. Canada, George F. Wohlford, Michele Golino, Dave Dixon, Benjamin W. Van Tassell, Antonio Abbate

Summary: Anakinra, a recombinant human interleukin-1 receptor antagonist, is effective for treating inflammatory diseases. This study compared the stability of anakinra in glass and plastic syringes, and evaluated its anti-inflammatory and clinical effects in patients with ST-segment elevation myocardial infarction. The findings indicate that anakinra stored in plastic syringes is as biologically and clinically effective as in glass syringes, suggesting the feasibility of using plastic syringes in clinical trials.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs?

Anurag Mehta, Dave L. Dixon, Anum Saeed, Michael S. Kelly, Martha Gulati, Michael D. Shapiro, Laurence S. Sperling, Salim S. Virani

Summary: This review discusses the effectiveness, safety, and real-world utilization of statins, and proposes reclassifying them as nonprescription drugs to improve access and availability for patients.

CURRENT CARDIOLOGY REPORTS (2023)

Add to Collection

Review Pharmacology & Pharmacy

Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies

Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael S. Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon

Summary: Lipoprotein(a), or Lp(a), is structurally similar to low-density lipoprotein (LDL) but contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined and are not greatly affected by diet and lifestyle interventions.

PHARMACOTHERAPY (2023)

Add to Collection

Article Oncology

Oncologists' responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study

Teresa M. M. Salgado, Rotana M. M. Radwan, Erin Hickey Zacholski, Emily Mackler, Tonya M. M. Buffington, Kerri T. T. Musselman, William J. J. Irvin Jr, Jennifer M. M. Perkins, Trang N. N. Le, Dave L. L. Dixon, Karen B. B. Farris, Vanessa B. B. Sheppard, Resa M. M. Jones

Summary: The purpose of this study was to assess oncologists' responsibility, comfort, and knowledge in managing hyperglycemia in patients undergoing chemotherapy. The study found that oncologists expected endocrinologists/diabetologists and primary care physicians to manage hyperglycemia, and referred patients to them frequently. The biggest barriers identified were long wait times and patients' providers being outside of the oncologist's institution. New models that provide prompt and coordinated care are needed.

SUPPORTIVE CARE IN CANCER (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology

Salim S. Virani, Karen Aspry, Dave L. Dixon, Keith C. Ferdinand, Paul A. Heidenreich, Elizabeth J. Jackson, Terry A. Jacobson, Janice L. McAlister, David R. Neff, Martha Gulati, Christie M. Ballantyne

Summary: Despite the established role of LDL-C as a major risk factor for CVD, national quality assurance metrics no longer include LDL-C measurement as a required performance metric. This article reviews the history of LDL-C as a quality and performance metric and presents rationales for re-establishing LDL-C measurement to improve cholesterol control and reduce CVD morbidity and mortality, healthcare disparities, and costs.

AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Overview of clinical practice guideline development, application to pharmacy practice, and roles for pharmacists

Dave L. Dixon, Ila M. Harris, Raniah Aljadeed, Keri C. Anderson, Anna Aycock, Craig Beavers, Elizabeth J. Beckman, Diana Isaacs, Emily McCoy, Anna Sandler, Joseph J. Saseen, Shivali Singh, Jamie Wagner

Summary: All healthcare professionals have a responsibility to incorporate evidence-based medicine into their practice to ensure the best patient care. Clinical practice guidelines play a major role in helping clinicians implement evidence and improve patient outcomes, but there is inconsistent application of best practices in published guidelines.

JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (2023)

Add to Collection

Meeting Abstract Economics

CONTRIBUTION OF CLINICAL PHARMACY SERVICES TO THE ACHIEVEMENT OF DIABETES AND HYPERTENSIONRELATED QUALITY MEASURES AMONG MEDICARE PATIENTS

T. Wagner, M. R. Barker, B. A. Martin, P. Q. Ngo, E. E. Ko, M. M. Squadrito, J. D. Frerichs, K. T. Musselman, Y. Shin, D. L. Dixon, R. M. Jones, T. Salgado

VALUE IN HEALTH (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.